Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HUMA NASDAQ:MGTX NASDAQ:PHAR NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$0.92$0.99$0.55▼$2.84$205.24M2.458.26 million shs11.29 million shsMGTXMeiraGTx$11.32$9.73$6.07▼$11.85$1.05B1.26757,802 shs2.52 million shsPHARPharming Group$12.69-1.4%$14.28$9.54▼$21.34$895.82M-0.048,421 shs3,254 shsXNCRXencor$12.64$12.12$6.92▼$18.69$937.13M0.92682,553 shs1.82 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte0.00%-12.38%-11.96%+8.71%-59.98%MGTXMeiraGTx0.00%+18.04%+22.51%+47.97%+78.55%PHARPharming Group0.00%-0.98%+0.67%-20.77%+19.67%XNCRXencor0.00%+2.51%+11.76%+4.90%+48.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$0.92$0.99$0.55▼$2.84$205.24M2.458.26 million shs11.29 million shsMGTXMeiraGTx$11.32$9.73$6.07▼$11.85$1.05B1.26757,802 shs2.52 million shsPHARPharming Group$12.69-1.4%$14.28$9.54▼$21.34$895.82M-0.048,421 shs3,254 shsXNCRXencor$12.64$12.12$6.92▼$18.69$937.13M0.92682,553 shs1.82 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte0.00%-12.38%-11.96%+8.71%-59.98%MGTXMeiraGTx0.00%+18.04%+22.51%+47.97%+78.55%PHARPharming Group0.00%-0.98%+0.67%-20.77%+19.67%XNCRXencor0.00%+2.51%+11.76%+4.90%+48.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHUMAHumacyte 2.75Moderate Buy$6.25576.11% UpsideMGTXMeiraGTx 2.75Moderate Buy$25.83128.21% UpsidePHARPharming Group 2.40Hold$38.33202.19% UpsideXNCRXencor 2.40Hold$24.5093.83% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, XNCR, PHAR, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026HUMAHumacyte TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1.50 ➝ $1.256/16/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/11/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.006/8/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/1/2026HUMAHumacyte BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$2.005/26/2026MGTXMeiraGTx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.005/15/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $25.005/13/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026XNCRXencor JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$13.00 ➝ $14.00(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHUMAHumacyte$2.04M100.61N/AN/A$0.02 per share46.22MGTXMeiraGTx$81.39M12.88N/AN/A($0.07) per share-161.71PHARPharming Group$376.13M2.38$0.20 per share64.19$3.95 per share3.21XNCRXencor$125.58M7.46N/AN/A$8.90 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%8/10/2026 (Estimated)MGTXMeiraGTx-$114.20M-$1.48N/AN/AN/A-151.12%-1,065.47%-54.96%8/13/2026 (Estimated)PHARPharming Group$2.85M$0.1679.2919.52N/A3.30%4.64%2.55%7/30/2026 (Estimated)XNCRXencor-$91.92M-$2.29N/AN/AN/A-177.10%-28.77%-20.52%8/5/2026 (Estimated)Latest HUMA, XNCR, PHAR, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MGTXMeiraGTx-$0.6060-$0.57+$0.0360-$0.57$17.00 million$0.29 million5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million5/6/2026Q1 2026XNCRXencor-$0.7468-$1.71-$0.9632-$1.71$27.86 million$4.52 million3/27/2026Q4 2025HUMAHumacyte-$0.13-$0.13N/A-$0.13$1.35 million$0.47 million3/26/2026Q4 2025MGTXMeiraGTx-$0.60$0.19+$0.79$0.19$3.87 million$75.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHUMAHumacyteN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHUMAHumacyte5.463.933.32MGTXMeiraGTxN/A0.550.55PHARPharming Group0.352.632.06XNCRXencorN/A6.576.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHUMAHumacyte44.71%MGTXMeiraGTx67.48%PHARPharming Group0.03%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipHUMAHumacyte3.10%MGTXMeiraGTx7.40%PHARPharming Group2.07%XNCRXencor5.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHUMAHumacyte150222.02 million215.14 millionOptionableMGTXMeiraGTx30092.61 million85.76 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableXNCRXencor28074.14 million70.38 millionOptionableHUMA, XNCR, PHAR, and MGTX HeadlinesRecent News About These CompaniesXencor Updates Outlook Amid Ultomiris Royalty DisputeJune 19 at 11:20 PM | theglobeandmail.comXencor Shareholders Approve Directors, Incentive Plan AmendmentsJune 18, 2026 | tipranks.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Hold" from AnalystsJune 18, 2026 | americanbankingnews.comXencor (NASDAQ:XNCR) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?June 17, 2026 | americanbankingnews.comXencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets CautionJune 15, 2026 | uk.finance.yahoo.comIncyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trialMay 30, 2026 | seekingalpha.comJefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCRMay 25, 2026 | marketbeat.comXencor IncMay 18, 2026 | money.usnews.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comXencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comThese Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under ThreatMay 8, 2026 | finance.yahoo.comXencor: Q1 Earnings SnapshotMay 6, 2026 | ctpost.comCXencor (XNCR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comXencor Reports First Quarter 2026 Financial ResultsMay 6, 2026 | businesswire.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 TranscriptMay 5, 2026 | seekingalpha.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 - SlideshowMay 5, 2026 | seekingalpha.comXencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDWMay 4, 2026 | businesswire.comJP Morgan Downgrades Xencor (XNCR)March 25, 2026 | msn.comXencor (XNCR) Receives a Buy from WedbushMarch 17, 2026 | theglobeandmail.comXencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptMarch 11, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026Eli Lilly Wins Back CVS Health, Reverting Novo's AdvantageBy Leo Miller | June 2, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyBy Chris Markoch | May 23, 2026Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?By Jessica Mitacek | May 28, 2026HUMA, XNCR, PHAR, and MGTX Company DescriptionsHumacyte NASDAQ:HUMA$0.92 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.94 +0.01 (+1.47%) As of 05:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.MeiraGTx NASDAQ:MGTX$11.32 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$11.91 +0.59 (+5.20%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Pharming Group NASDAQ:PHAR$12.68 -0.19 (-1.44%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$12.89 +0.21 (+1.62%) As of 06/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Xencor NASDAQ:XNCR$12.64 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$12.74 +0.10 (+0.82%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
